Skip to main content

Table 3 CBCT cortical and medullary lysis change (N = 14) and MRI change (N = 14) in patients after treatment

From: Mandibular involvement in SAPHO syndrome: a retrospective study

Treatmenta

CT

MRI

N

Remissionb

Progressionc

N

Muscle edema

Subcutaneous soft tissue swelling

Bone marrow edema

Periosteitis

Synovial thickening of TMJ

R

S/P

R

S/P

R

S/P

R

S/P

R

S/P

TNFi

4

2

2

3

1

1

0

1

0

3

0

1

0

0

TNFi + CS

1

0

1

0

–

–

–

–

–

–

–

–

–

–

TNFi + MTX

0

–

–

3

1

2

0

1

1

2

0

0

0

0

TNFi + TwFH

0

–

–

1

0

1

0

0

0

1

0

0

0

0

BP

6

6

0

5

3

1

1

0

4

1

1

0

1

0

BP + CS

1

1

0

0

–

–

–

–

–

–

–

–

–

–

BP + TwFH

1

1

0

1

0

0

0

0

0

1

0

0

1

0

BP + TNFi

2

2

0

1

1

0

0

0

1

0

0

0

0

0

TwFH + CS

0

–

–

4

4

0

1

0

2

2

1

1

3

0

CS

2

0

2

3

2

1

1

0

2

1

0

0

1

1

CS + MTX

1

1

0

0

–

–

–

–

–

–

–

–

–

–

IL-6 inhibitor

1

0

1

0

–

–

–

–

–

–

–

–

–

–

  1. R remission, S/P stable disease/Progression, TNFi tumour necrosis factor-α inhibitor, MTX methotrexate, TwFH Tripterygium wilfordii Hook F, CS Corticosteroids, TMJ temporomandibular joint, BP bisphosphonate
  2. aOne patient could change the drug due to its uneffectiveness during the follow-up
  3. bRemission: a new or increased area of cortical or medullary lysis on CBCT, or a new or increased area or increased intensity of the high-intensity signal of bone marrow or surrounding soft tissue on the T2-weighted image
  4. cProgression: a decreased area of cortical or medullary lysis on CBCT, or a decreased area or intensity of the high-intensity signal of bone marrow or surrounding soft tissue on the T2-weighted image